Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ASRT 
Assertio Therapeutics Inc (ASRT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ASRT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.69
1 Year Target Price $2.69
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.28% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 78.27M USD | Price to earnings Ratio - | 1Y Target Price 2.69 |
Price to earnings Ratio - | 1Y Target Price 2.69 | ||
Volume (30-day avg) 4 | Beta 0.35 | 52 Weeks Range 0.51 - 1.38 | Updated Date 09/14/2025 |
52 Weeks Range 0.51 - 1.38 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.97% | Operating Margin (TTM) -14.49% |
Management Effectiveness
Return on Assets (TTM) -7.96% | Return on Equity (TTM) -38.4% |
Valuation
Trailing PE - | Forward PE 14.99 | Enterprise Value 19961687 | Price to Sales(TTM) 0.67 |
Enterprise Value 19961687 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 4.03 | Shares Outstanding 96239600 | Shares Floating 85632094 |
Shares Outstanding 96239600 | Shares Floating 85632094 | ||
Percent Insiders 2.51 | Percent Institutions 26.86 |
Upturn AI SWOT
Assertio Therapeutics Inc
Company Overview
History and Background
Assertio Therapeutics Inc. was founded in 1995 as Depomed, Inc., focused on developing pharmaceutical products. Over time, it transitioned, rebranded as Assertio, and shifted its strategy towards acquiring and commercializing established branded products. The company faced financial challenges but restructured and refocused.
Core Business Areas
- Neurology: Focuses on treatments for neurological conditions. Currently its primary asset is Otrexup (methotrexate) which is primarily for use in treatment for severe active rheumatoid arthritis.
- Pain and Inflammation: Includes products aimed at managing pain and inflammation. This market segment is currently in decline, due to legal risks that caused the company to take a loss on the products.
Leadership and Structure
The leadership team includes Dan Peisert (President and CEO) and John Bicos (CFO). The organizational structure is typical of a pharmaceutical company with departments for R&D, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Otrexup (methotrexate): A subcutaneous auto-injector of methotrexate for the treatment of severe active rheumatoid arthritis. Market share data not publicly available. Competitors include other methotrexate formulations and biologics. Revenue is the main driver of profits for the company.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with trends including increasing demand for specialty medications, growing focus on biosimilars, and evolving regulatory landscapes.
Positioning
Assertio Therapeutics Inc. positions itself as a specialty pharmaceutical company acquiring and commercializing products within niche markets.
Total Addressable Market (TAM)
The TAM for rheumatoid arthritis treatments is substantial, estimated in the billions of dollars globally. Assertio focuses on a segment of this market with Otrexup. The size of the market in rheumatoid arthritis treatment is large, but Assertio has a specific subset of the overall Rheumatoid Arthritis drug treatment market.
Upturn SWOT Analysis
Strengths
- Niche market focus
- Established product portfolio
- Experienced management team
Weaknesses
- Limited pipeline
- Reliance on a few key products
- Historical debt burden
Opportunities
- Strategic acquisitions
- Expansion into new therapeutic areas
- Partnerships and collaborations
Threats
- Generic competition
- Regulatory changes
- Patent expirations
- Product Liability lawsuits
Competitors and Market Share
Key Competitors
- VRX
- AGN
- RDY
Competitive Landscape
Assertio Therapeutics Inc. faces competition from larger pharmaceutical companies with greater resources. Its niche focus and targeted acquisitions are advantages.
Major Acquisitions
Zanaflex Capsules and Tablets
- Year: 2019
- Acquisition Price (USD millions): 170
- Strategic Rationale: Expanded pain management portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth will be assessed based on past revenue and earnings trends.
Future Projections: Future growth projections will be based on analyst estimates and company guidance. Future growth is estimated to be around 2% for 2024 and 2025.
Recent Initiatives: Recent initiatives include focusing on core products and exploring strategic acquisitions.
Summary
Assertio Therapeutics is a specialty pharmaceutical company focused on niche markets. The company is growing slowly and is focusing on rheumatoid arthritis treatments. It's success is highly dependent on the company's legal struggles being resolved. It also needs to explore strategic acquisitions to diversify its product portfolio.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q)
- Company website
- Analyst reports
- Financial news outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Assertio Therapeutics Inc
Exchange NASDAQ | Headquaters Lake Forest, IL, United States | ||
IPO Launch date 1997-11-05 | CEO & Director Mr. Brendan P. O'Grady | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 58 | Website https://www.assertiotx.com |
Full time employees 58 | Website https://www.assertiotx.com | ||
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.